|MDACC Study No:||RTOG0912 (clinicaltrials.gov NCT No: NCT01236547)|
|Title:||A Randomized Phase II Study of Concurrent Intensity Modulated Radiation Therapy (IMRT), Paclitaxel and Pazopanib (NSC 737754)/Placebo, for the Treatment of Anaplastic Thyroid Cancer|
|Principal Investigator:||Gary B. Gunn|
|Treatment Agent:||Intensity Modulated Radiotherapy; Paclitaxel; Pazopanib; Placebo |
|Study Description:||The goal of this clinical research study is to learn if adding pazopanib to |
paclitaxel and radiation (chemoradiotherapy) is safe and tolerable.
Pazopanib is designed to block the growth of blood vessels that supply
nutrients needed for tumor growth. This may prevent or slow the growth of
Paclitaxel is designed to block cancer cells from dividing, which may cause
them to die.
A placebo is not a drug. It looks like the study drug but is not designed to
treat any disease or illness. It is designed to be compared with a study drug
to learn if the study drug has any real effect.